Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for TARS

Stock Name	Tarsus Pharmaceuticals Inc
Ticker	TARS(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US87650L1035

Show aggregate TARS holdings

News associated with TARS

Blair William & Co. IL Trims Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Blair William & Co. IL decreased its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 58.1% during the first quarter, Holdings Channel reports. The fund owned 11,416 shares of the company’s stock after selling 15,814 shares during the period. Blair William & Co. IL’s holdings in Tarsus Pharmaceuticals were worth $586,000 […] - 2025-08-11 05:52:54
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Recommendation of “Buy” from Brokerages: Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) have earned a consensus rating of “Buy” from the seven analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to […] - 2025-08-06 03:06:50
Arizona State Retirement System Buys 470 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Arizona State Retirement System lifted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 6.1% during the first quarter, Holdings Channel.com reports. The firm owned 8,182 shares of the company’s stock after acquiring an additional 470 shares during the period. Arizona State Retirement System’s holdings in Tarsus Pharmaceuticals were worth $420,000 […] - 2025-07-23 05:44:46
Brokerages Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) PT at $66.67: Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) have been assigned a consensus recommendation of “Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to […] - 2025-06-20 02:36:52
GAMMA Investing LLC Purchases 13,115 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): GAMMA Investing LLC grew its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 36,430.6% in the first quarter, Holdings Channel reports. The fund owned 13,151 shares of the company’s stock after acquiring an additional 13,115 shares during the quarter. GAMMA Investing LLC’s holdings in Tarsus Pharmaceuticals were worth $676,000 at the end of […] - 2025-06-19 04:06:59
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 18.7% during the fourth quarter, HoldingsChannel reports. The fund owned 69,826 shares of the company’s stock after acquiring an additional 10,991 shares during the quarter. UBS AM a distinct […] - 2025-06-05 06:14:53
Nuveen Asset Management LLC Has $6.95 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Nuveen Asset Management LLC trimmed its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 10.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 125,539 shares of the company’s stock after selling 15,186 shares during the quarter. Nuveen Asset […] - 2025-05-30 05:04:50
Tarsus Pharmaceuticals (NASDAQ:TARS) Raised to Buy at HC Wainwright: Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) was upgraded by equities research analysts at HC Wainwright to a “buy” rating in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The firm currently has a $72.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 71.22% from the […] - 2025-05-29 02:15:10
Two Sigma Advisers LP Has $2.96 Million Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Two Sigma Advisers LP reduced its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 79.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 53,500 shares of the company’s stock after selling 202,900 shares during the quarter. Two Sigma […] - 2025-05-28 07:09:12
Two Sigma Investments LP Has $5.05 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Two Sigma Investments LP lowered its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 69.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 91,171 shares of the company’s stock after selling 204,832 shares during the quarter. […] - 2025-05-28 05:04:57
Tarsus Pharmaceuticals (NASDAQ:TARS) and Dyadic International (NASDAQ:DYAI) Critical Survey: Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) and Dyadic International (NASDAQ:DYAI – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends. Earnings and Valuation This table compares Tarsus […] - 2025-05-27 02:17:08
Analysts Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Target Price at $66.33: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has earned an average recommendation of “Buy” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation […] - 2025-05-26 03:08:58
Dimensional Fund Advisors LP Cuts Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Dimensional Fund Advisors LP reduced its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 15.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 341,305 shares of the company’s stock after selling 62,658 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Tarsus Pharmaceuticals were worth $18,897,000 at […] - 2025-05-08 05:25:05
The Goldman Sachs Group Forecasts Strong Price Appreciation for Tarsus Pharmaceuticals (NASDAQ:TARS) Stock: Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) had its target price upped by investment analysts at The Goldman Sachs Group from $46.00 to $51.00 in a report released on Monday,Benzinga reports. The firm currently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price would suggest a potential upside of 9.80% from […] - 2025-05-07 02:22:52
Barclays PLC Sells 23,999 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Barclays PLC trimmed its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 24.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,664 shares of the company’s stock after selling 23,999 shares during the period. […] - 2025-04-28 05:01:20
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Legal & General Group Plc: Legal & General Group Plc trimmed its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 2.1% during the fourth quarter, Holdings Channel reports. The fund owned 26,595 shares of the company’s stock after selling 560 shares during the quarter. Legal & General Group Plc’s holdings in Tarsus Pharmaceuticals were worth $1,473,000 […] - 2025-04-27 05:42:58
Wells Fargo & Company MN Has $3.16 Million Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Wells Fargo & Company MN raised its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 44.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 57,004 shares of the company’s stock after buying an additional 17,451 shares during the period. […] - 2025-04-24 04:32:51
Geode Capital Management LLC Buys 3,014 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Geode Capital Management LLC lifted its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 0.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 838,804 shares of the company’s stock after buying an additional 3,014 shares during the quarter. Geode […] - 2025-04-15 05:00:56
Pictet Asset Management Holding SA Invests $284,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Pictet Asset Management Holding SA bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) during the fourth quarter, HoldingsChannel reports. The institutional investor bought 5,130 shares of the company’s stock, valued at approximately $284,000. A number of other institutional investors and hedge funds have also recently bought and sold shares of the […] - 2025-04-11 06:24:52
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Vanguard Group Inc.: Vanguard Group Inc. boosted its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 0.9% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 2,115,162 shares of the company’s stock after buying an additional 17,839 shares during the period. Vanguard Group Inc. owned 0.06% of Tarsus Pharmaceuticals worth $117,117,000 as […] - 2025-04-09 04:42:52
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Up After Strong Earnings: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) gapped up prior to trading on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $45.54, but opened at $47.44. Tarsus Pharmaceuticals shares last traded at $44.83, with a volume of 251,757 shares. The company reported ($0.60) earnings per share […] - 2025-02-27 05:10:47
Allspring Global Investments Holdings LLC Has $10.03 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Allspring Global Investments Holdings LLC cut its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 14.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 181,122 shares of the company’s stock after selling 29,409 shares during the period. Allspring […] - 2025-02-19 07:08:18
Bleakley Financial Group LLC Makes New $323,000 Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Bleakley Financial Group LLC bought a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) in the fourth quarter, Holdings Channel reports. The firm bought 5,825 shares of the company’s stock, valued at approximately $323,000. A number of other large investors have also recently added to or reduced their stakes in the […] - 2025-02-12 06:57:10
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of “Buy” from Brokerages: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has been assigned an average recommendation of “Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the […] - 2025-02-12 04:40:57
Tarsus Pharmaceuticals (NASDAQ:TARS) Given Buy Rating at Guggenheim: Guggenheim reissued their buy rating on shares of Tarsus Pharmaceuticals (NASDAQ:TARS – Free Report) in a research report released on Monday morning,Benzinga reports. A number of other equities analysts have also weighed in on the stock. Barclays boosted their price objective on shares of Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an […] - 2025-02-11 05:09:04

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc TARS holdings

Date	Number of TARS Shares Held	Base Market Value of TARS Shares	Local Market Value of TARS Shares	Change in TARS Shares Held	Change in TARS Base Value	Current Price per TARS Share Held	Previous Price per TARS Share Held
2025-12-11 (Thursday)	8,968	USD 732,686	USD 732,686	0	USD 3,408	USD 81.7	USD 81.32
2025-12-10 (Wednesday)	8,968	USD 729,278	USD 729,278	0	USD 15,874	USD 81.32	USD 79.55
2025-12-09 (Tuesday)	8,968	USD 713,404	USD 713,404	0	USD -24,035	USD 79.55	USD 82.23
2025-12-08 (Monday)	8,968	USD 737,439	USD 737,439	0	USD 4,126	USD 82.23	USD 81.77
2025-12-05 (Friday)	8,968	USD 733,313	USD 733,313	0	USD -538	USD 81.77	USD 81.8299
2025-12-04 (Thursday)	8,968	USD 733,851	USD 733,851	0	USD -449	USD 81.8299	USD 81.88
2025-12-03 (Wednesday)	8,968	USD 734,300	USD 734,300	-155	USD 9,569	USD 81.88	USD 79.44
2025-12-02 (Tuesday)	9,123	USD 724,731	USD 724,731	62	USD 123	USD 79.44	USD 79.97
2025-12-01 (Monday)	9,061	USD 724,608	USD 724,608	0	USD 90	USD 79.97	USD 79.96
2025-11-28 (Friday)	9,061	USD 724,518	USD 724,518	0	USD -4,893	USD 79.96	USD 80.5001
2025-11-27 (Thursday)	9,061	USD 729,411	USD 729,411	0	USD 0	USD 80.5001	USD 80.5001
2025-11-26 (Wednesday)	9,061	USD 729,411	USD 729,411	0	USD 14,679	USD 80.5001	USD 78.88
2025-11-25 (Tuesday)	9,061	USD 714,732	USD 714,732	-93	USD -36,903	USD 78.88	USD 82.11

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of TARS by Blackrock for IE00B3VWM098

Show aggregate share trades of TARS

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-03 SELL -155 81.880* 51.15 Profit of 7,928 on sale
2025-12-02 BUY 62 79.440* 51.02
2025-11-25 SELL -93 78.880* 50.31 Profit of 4,679 on sale
2025-11-24 SELL -93 82.110* 50.16 Profit of 4,665 on sale
2025-11-17 SELL -341 74.170* 49.49 Profit of 16,876 on sale
2025-11-12 SELL -31 74.810* 49.12 Profit of 1,523 on sale
2025-11-06 SELL -31 68.090* 48.67 Profit of 1,509 on sale
2025-11-05 SELL -310 71.950 67.500 67.945 USD -21,063 48.57 Loss of -6,008 on sale
2025-11-04 SELL -62 71.500* 48.45 Profit of 3,004 on sale
2025-11-03 SELL -62 70.160 67.500 67.766 USD -4,201 48.33 Loss of -1,205 on sale
2025-10-28 BUY 93 67.560 68.310 68.235 USD 6,346 47.91
2025-10-24 SELL -31 66.060 69.130 68.823 USD -2,134 47.70 Loss of -655 on sale
2025-10-15 BUY 186 74.950 75.010 75.004 USD 13,951 46.75
2025-10-02 BUY 31 58.770 59.510 59.436 USD 1,843 46.57
2025-09-30 BUY 62 59.430 59.770 59.736 USD 3,704 46.44
2025-08-21 SELL -31 56.560 56.600 56.596 USD -1,754 46.16 Loss of -323 on sale
2025-07-31 BUY 93 38.820 40.490 40.323 USD 3,750 46.15
2025-07-28 SELL -31 41.750 42.250 42.200 USD -1,308 46.25 Profit of 126 on sale
2025-06-30 SELL -62 40.510 41.500 41.401 USD -2,567 46.84 Profit of 337 on sale
2025-06-25 SELL -31 40.200 42.000 41.820 USD -1,296 46.97 Profit of 160 on sale
2025-06-20 SELL -62 40.650 41.300 41.235 USD -2,557 47.11 Profit of 364 on sale
2025-05-23 BUY 31 42.980 43.230 43.205 USD 1,339 47.92
2025-05-19 SELL -31 45.010 45.170 45.154 USD -1,400 48.05 Profit of 90 on sale
2025-05-15 SELL -93 43.500 43.950 43.905 USD -4,083 48.13 Profit of 393 on sale
2025-05-12 SELL -31 44.200 46.250 46.045 USD -1,427 48.27 Profit of 69 on sale
2025-05-09 SELL -31 44.760 47.320 47.064 USD -1,459 48.30 Profit of 38 on sale
2025-04-30 SELL -31 51.910 52.100 52.081 USD -1,615 48.30 Loss of -117 on sale
2025-04-24 SELL -62 49.970 50.500 50.447 USD -3,128 48.23 Loss of -138 on sale
2025-04-17 SELL -31 49.250 50.300 50.195 USD -1,556 48.17 Loss of -63 on sale
2025-04-15 SELL -93 49.120 49.800 49.732 USD -4,625 48.15 Loss of -147 on sale
2025-04-14 SELL -93 48.720 48.725 48.724 USD -4,531 48.14 Loss of -54 on sale
2025-04-09 SELL -124 45.870 46.310 46.266 USD -5,737 48.23 Profit of 244 on sale
2025-04-07 SELL -217 47.490 49.040 48.885 USD -10,608 48.28 Loss of -131 on sale
2025-04-04 SELL -310 47.020 48.800 48.622 USD -15,073 48.30 Loss of -101 on sale
2025-03-31 BUY 31 51.370 51.630 51.604 USD 1,600 48.21
2025-03-19 SELL -62 49.550 49.730 49.712 USD -3,082 47.93 Loss of -110 on sale
2025-03-14 SELL -186 48.090 48.230 48.216 USD -8,968 47.96 Loss of -48 on sale
2025-03-13 SELL -62 46.470 48.955 48.707 USD -3,020 47.98 Loss of -45 on sale
2025-03-12 SELL -1,054 47.100 49.900 49.620 USD -52,299 47.99 Loss of -1,714 on sale
2025-03-07 SELL -62 46.470 46.770 46.740 USD -2,898 48.08 Profit of 83 on sale
2025-03-06 SELL -93 43.570 44.390 44.308 USD -4,121 48.15 Profit of 357 on sale
2025-03-03 SELL -31 42.720 44.750 44.547 USD -1,381 48.36 Profit of 118 on sale
2025-02-28 SELL -45,552 44.480 44.810 44.777 USD -2,039,682 48.42 Profit of 165,894 on sale
2025-02-26 SELL -151 42.560 43.760 43.640 USD -6,590 48.60 Profit of 749 on sale
2025-02-25 SELL -453 41.290 47.630 46.996 USD -21,289 48.73 Profit of 784 on sale
2025-02-18 BUY 755 50.850 51.280 51.237 USD 38,684 48.75
2025-02-13 BUY 151 52.230 53.220 53.121 USD 8,021 48.62
2025-02-12 BUY 151 52.330 52.970 52.906 USD 7,989 48.54
2025-02-11 BUY 453 51.220 52.005 51.927 USD 23,523 48.49
2025-02-06 BUY 1,359 53.320 56.960 56.596 USD 76,914 48.21
2025-01-27 BUY 151 51.450 54.080 53.817 USD 8,126 47.10
2024-12-30 BUY 755 54.700 57.140 56.896 USD 42,956 46.51
2024-12-06 BUY 604 51.790 52.020 51.997 USD 31,406 46.06
2024-12-05 BUY 151 50.320 51.730 51.589 USD 7,790 45.92
2024-12-04 BUY 755 51.640 52.130 52.081 USD 39,321 45.71
2024-11-29 BUY 755 52.450 52.650 52.630 USD 39,736 45.07
2024-11-27 BUY 604 50.840 51.460 51.398 USD 31,044 44.56
2024-11-26 BUY 151 49.660 51.250 51.091 USD 7,715 44.33
2024-11-25 SELL -10,543 48.320 49.090 49.013 USD -516,744 44.14 Loss of -51,346 on sale
2024-11-21 BUY 915 46.400 47.600 47.480 USD 43,444 43.81
2024-11-20 BUY 549 46.580 47.370 47.291 USD 25,963 43.65
2024-11-18 BUY 2,196 44.630 46.790 46.574 USD 102,277 43.39
2024-11-12 BUY 1,464 47.570 49.623 49.418 USD 72,348 43.11
2024-11-08 BUY 915 49.420 49.900 49.852 USD 45,615 42.66
2024-11-07 BUY 2,730 46.790 47.400 47.339 USD 129,235 42.34
2024-11-06 BUY 364 46.800 51.590 51.111 USD 18,604 41.97
2024-10-31 BUY 182 44.490 45.250 45.174 USD 8,222 40.00
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-03	SELL	-155			81.880*		51.15 Profit of 7,928 on sale
2025-12-02	BUY	62			79.440*		51.02
2025-11-25	SELL	-93			78.880*		50.31 Profit of 4,679 on sale
2025-11-24	SELL	-93			82.110*		50.16 Profit of 4,665 on sale
2025-11-17	SELL	-341			74.170*		49.49 Profit of 16,876 on sale
2025-11-12	SELL	-31			74.810*		49.12 Profit of 1,523 on sale
2025-11-06	SELL	-31			68.090*		48.67 Profit of 1,509 on sale
2025-11-05	SELL	-310	71.950	67.500	67.945	USD -21,063	48.57 Loss of -6,008 on sale
2025-11-04	SELL	-62			71.500*		48.45 Profit of 3,004 on sale
2025-11-03	SELL	-62	70.160	67.500	67.766	USD -4,201	48.33 Loss of -1,205 on sale
2025-10-28	BUY	93	67.560	68.310	68.235	USD 6,346	47.91
2025-10-24	SELL	-31	66.060	69.130	68.823	USD -2,134	47.70 Loss of -655 on sale
2025-10-15	BUY	186	74.950	75.010	75.004	USD 13,951	46.75
2025-10-02	BUY	31	58.770	59.510	59.436	USD 1,843	46.57
2025-09-30	BUY	62	59.430	59.770	59.736	USD 3,704	46.44
2025-08-21	SELL	-31	56.560	56.600	56.596	USD -1,754	46.16 Loss of -323 on sale
2025-07-31	BUY	93	38.820	40.490	40.323	USD 3,750	46.15
2025-07-28	SELL	-31	41.750	42.250	42.200	USD -1,308	46.25 Profit of 126 on sale
2025-06-30	SELL	-62	40.510	41.500	41.401	USD -2,567	46.84 Profit of 337 on sale
2025-06-25	SELL	-31	40.200	42.000	41.820	USD -1,296	46.97 Profit of 160 on sale
2025-06-20	SELL	-62	40.650	41.300	41.235	USD -2,557	47.11 Profit of 364 on sale
2025-05-23	BUY	31	42.980	43.230	43.205	USD 1,339	47.92
2025-05-19	SELL	-31	45.010	45.170	45.154	USD -1,400	48.05 Profit of 90 on sale
2025-05-15	SELL	-93	43.500	43.950	43.905	USD -4,083	48.13 Profit of 393 on sale
2025-05-12	SELL	-31	44.200	46.250	46.045	USD -1,427	48.27 Profit of 69 on sale
2025-05-09	SELL	-31	44.760	47.320	47.064	USD -1,459	48.30 Profit of 38 on sale
2025-04-30	SELL	-31	51.910	52.100	52.081	USD -1,615	48.30 Loss of -117 on sale
2025-04-24	SELL	-62	49.970	50.500	50.447	USD -3,128	48.23 Loss of -138 on sale
2025-04-17	SELL	-31	49.250	50.300	50.195	USD -1,556	48.17 Loss of -63 on sale
2025-04-15	SELL	-93	49.120	49.800	49.732	USD -4,625	48.15 Loss of -147 on sale
2025-04-14	SELL	-93	48.720	48.725	48.724	USD -4,531	48.14 Loss of -54 on sale
2025-04-09	SELL	-124	45.870	46.310	46.266	USD -5,737	48.23 Profit of 244 on sale
2025-04-07	SELL	-217	47.490	49.040	48.885	USD -10,608	48.28 Loss of -131 on sale
2025-04-04	SELL	-310	47.020	48.800	48.622	USD -15,073	48.30 Loss of -101 on sale
2025-03-31	BUY	31	51.370	51.630	51.604	USD 1,600	48.21
2025-03-19	SELL	-62	49.550	49.730	49.712	USD -3,082	47.93 Loss of -110 on sale
2025-03-14	SELL	-186	48.090	48.230	48.216	USD -8,968	47.96 Loss of -48 on sale
2025-03-13	SELL	-62	46.470	48.955	48.707	USD -3,020	47.98 Loss of -45 on sale
2025-03-12	SELL	-1,054	47.100	49.900	49.620	USD -52,299	47.99 Loss of -1,714 on sale
2025-03-07	SELL	-62	46.470	46.770	46.740	USD -2,898	48.08 Profit of 83 on sale
2025-03-06	SELL	-93	43.570	44.390	44.308	USD -4,121	48.15 Profit of 357 on sale
2025-03-03	SELL	-31	42.720	44.750	44.547	USD -1,381	48.36 Profit of 118 on sale
2025-02-28	SELL	-45,552	44.480	44.810	44.777	USD -2,039,682	48.42 Profit of 165,894 on sale
2025-02-26	SELL	-151	42.560	43.760	43.640	USD -6,590	48.60 Profit of 749 on sale
2025-02-25	SELL	-453	41.290	47.630	46.996	USD -21,289	48.73 Profit of 784 on sale
2025-02-18	BUY	755	50.850	51.280	51.237	USD 38,684	48.75
2025-02-13	BUY	151	52.230	53.220	53.121	USD 8,021	48.62
2025-02-12	BUY	151	52.330	52.970	52.906	USD 7,989	48.54
2025-02-11	BUY	453	51.220	52.005	51.927	USD 23,523	48.49
2025-02-06	BUY	1,359	53.320	56.960	56.596	USD 76,914	48.21
2025-01-27	BUY	151	51.450	54.080	53.817	USD 8,126	47.10
2024-12-30	BUY	755	54.700	57.140	56.896	USD 42,956	46.51
2024-12-06	BUY	604	51.790	52.020	51.997	USD 31,406	46.06
2024-12-05	BUY	151	50.320	51.730	51.589	USD 7,790	45.92
2024-12-04	BUY	755	51.640	52.130	52.081	USD 39,321	45.71
2024-11-29	BUY	755	52.450	52.650	52.630	USD 39,736	45.07
2024-11-27	BUY	604	50.840	51.460	51.398	USD 31,044	44.56
2024-11-26	BUY	151	49.660	51.250	51.091	USD 7,715	44.33
2024-11-25	SELL	-10,543	48.320	49.090	49.013	USD -516,744	44.14 Loss of -51,346 on sale
2024-11-21	BUY	915	46.400	47.600	47.480	USD 43,444	43.81
2024-11-20	BUY	549	46.580	47.370	47.291	USD 25,963	43.65
2024-11-18	BUY	2,196	44.630	46.790	46.574	USD 102,277	43.39
2024-11-12	BUY	1,464	47.570	49.623	49.418	USD 72,348	43.11
2024-11-08	BUY	915	49.420	49.900	49.852	USD 45,615	42.66
2024-11-07	BUY	2,730	46.790	47.400	47.339	USD 129,235	42.34
2024-11-06	BUY	364	46.800	51.590	51.111	USD 18,604	41.97
2024-10-31	BUY	182	44.490	45.250	45.174	USD 8,222	40.00

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of TARS

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	252,801	0	426,166	59.3%
2025-09-18	137,976	0	230,324	59.9%
2025-09-17	350,436	5	543,379	64.5%
2025-09-16	169,762	23	341,917	49.7%
2025-09-15	188,220	0	351,011	53.6%
2025-09-12	173,824	19	536,802	32.4%
2025-09-11	254,169	0	587,029	43.3%
2025-09-10	130,049	21,726	202,273	64.3%
2025-09-09	81,081	0	152,616	53.1%
2025-09-08	127,262	13,834	268,329	47.4%
2025-09-05	111,598	0	279,260	40.0%
2025-09-04	157,740	6,413	224,745	70.2%
2025-09-03	72,242	1,200	191,629	37.7%
2025-09-02	219,449	0	325,874	67.3%
2025-08-29	62,133	0	140,050	44.4%
2025-08-28	50,541	0	159,808	31.6%
2025-08-27	36,919	0	92,543	39.9%
2025-08-26	63,628	0	154,058	41.3%
2025-08-25	72,109	0	148,872	48.4%
2025-08-22	80,786	0	201,829	40.0%
2025-08-21	73,646	0	231,979	31.7%
2025-08-20	93,401	891	221,733	42.1%
2025-08-19	42,418	0	137,197	30.9%
2025-08-18	116,541	20,164	304,699	38.2%
2025-08-15	133,688	400	335,133	39.9%
2025-08-14	81,791	328	173,473	47.1%
2025-08-13	119,902	0	340,392	35.2%
2025-08-12	113,528	0	262,067	43.3%
2025-08-11	247,112	200	586,919	42.1%
2025-08-08	164,594	0	266,105	61.9%
2025-08-07	425,029	300	765,615	55.5%
2025-08-06	173,644	39	252,868	68.7%
2025-08-05	89,019	5	111,443	79.9%
2025-08-04	104,357	20	207,097	50.4%
2025-08-01	273,972	0	370,178	74.0%
2025-07-31	170,413	0	271,101	62.9%
2025-07-30	92,228	0	317,929	29.0%
2025-07-29	142,684	0	285,141	50.0%
2025-07-28	123,438	31	191,764	64.4%
2025-07-25	123,025	336	162,520	75.7%
2025-07-24	122,485	10	171,350	71.5%
2025-07-23	115,791	0	149,653	77.4%
2025-07-22	84,089	10	133,731	62.9%
2025-07-21	196,108	151	244,905	80.1%
2025-07-18	290,801	482	509,804	57.0%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE